MedTrace Logo

Repetitive Transcranial Magnetic Stimulation for People With Etomidate Addiction (SToP-E-rTMS x Etomidate)

NCT07736742 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-30

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if high-frequency rTMS works to treat etomidate addiction in adults. It will also learn about the safety and tolerability of rTMS. The main questions it aims to answer are:

* Does active rTMS reduce craving, amount of etomidate use, frequency of etomidate use, and severity of etomidate use disorder?
* Does active rTMS improve cognitive biases related to delayed reward discounting and risk sensitivity?
* What side-effects do participants have when receiving rTMS?

Researchers will compare active rTMS to sham rTMS to see if active rTMS works to treat etomidate addiction.

Participants will:

* Receive active rTMS or sham rTMS over 4 weeks
* Complete 20 rTMS sessions in total
* Visit the clinic for treatment sessions and follow-up assessments
* Complete assessments of etomidate use, craving, withdrawal symptoms, mood symptoms, cognition, and decision-making

Attend follow-up assessments up to 6 months after baseline

Conditions

  • Etomidate Use Disorder
  • Repetitive Transcranial Magnetic Stimulation (rTMS)

Interventions

DEVICE

high-frequency Repetitive Transcranial Magnetic Stimulation

high-frequency rTMS using Magventure TMS system using the Coil Cool-B70 Active/Placebo Bended Butterfly coil is delivered at the dorsolateral prefrontal cortex of consented subjects

DEVICE

Repetitive transcranial magnetic stimulation

Sham rTMS will be delivered using the Coil Cool-B70 Active/Placebo Bended Butterfly coil, which generates a negligible magnetic field. The sham procedure will follow the same schedule as the active rTMS arm.

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Albert KK Chung · Department of Psychiatry, The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-08-31
Completion
2029-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07736742 on ClinicalTrials.gov